lunes, 30 de septiembre de 2019

FTC taking its time on Abbvie and Allergan

The Readout
Damian Garde

FTC taking its time on Abbvie and Allergan

There’s been tons of pressure on the Federal Trade Commission — from consumer groups, unions, and even politicians — to block AbbVie from successfully acquiring Allergan. The worry is that the $63 billion merger would create the fourth largest pharmaceutical company in the world — decreasing market competition in a time when drug prices are under intense scrutiny. 
Maybe the FTC is paying attention?

AbbVie and Allergan said late Friday they had received a second request for information from the antitrust regulator. The drug makers say that the inquiry was fully expected and that they still believe the deal will close early next year.

No hay comentarios: